Next-Gen Breakthroughs
New Researchers. New Possibilities.
LCFA welcomes two exceptional early career scientists to our research family. And the future of lung cancer care just got brighter.
Recently diagnosed with lung cancer?
Learn more about your lung cancer diagnosis. What questions should you be asking? What are the most important next steps? Know that you have options and remember that knowledge is power.
Meet the Researchers
View All-
-
Jonathan Villena-Vargas, MD
Thoracic Surgeon
Characterizing T cell PD-1 response in the tumor-draining lymph nodes of early-stage NSCLC patients
-
Kellie Smith, PhD
Leading an immunology lab in transformative cancer research
Immunotherapy in Early Stage Lung Cancer
Together we can make a lasting impact
Your support is vital to our mission of funding transformative science and improving survivorship.
Stay Connected
Hope, Research, and Impact in Your Inbox
Join our community and receive monthly updates on inspiring stories, groundbreaking research, and the early career researchers you’re helping to support. Sign up now to be part of the lung cancer fight!
-
Research is HOPE. Research will hopefully have me sitting here in #GiveMe20. Give me 20 years post-diagnosis.
Brandi Bryant, living with lung cancer
-
Your generosity is shaping future leaders in lung cancer research.
Kim Norris, Co-Founder and President
-
There is such tremendous hope for all patients with lung cancer right now.
Dr. Christine Lovly, LCFA Young Investigator
Word of the Day
EGFR
EGFR stands for epidermal growth factor receptor, which is a protein found on the surface of cells. Mutations in the EGFR gene can occur in certain types of lung cancer, particularly non-small cell lung cancer (NSCLC). Testing for EGFR mutations helps guide treatment decisions, as specific targeted therapies can be effective in treating lung cancer with EGFR mutations.